NIH funding opportunities

5 Dec 2023 (#39)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

1) *Generic Grant Writing Workshop and then the*

2) NIH Grant Writing Workshop

To prepare an application can take 4-18 months.

From submission to receiving a Notice of Award can take 10 months

Important Notices

NOT-MH-24-370 NIMH List of Human Genes Having Rare Variants with Strong Statistical Support for Association to Mental Health Traits. In 2018, the NIMH convened the National Advisory Mental Health Council (NAMHC) Workgroup on Genomics. The report emphasizes that NIMH should support research into genes that have appropriate, genome-wide evidence for association with a trait, whether the variation is rare or common. The report and a summary of recommendations are available at the NIMH website.

NOT-DC-24-008 Notice of Correction to Expiration Date for PAR-24-045, "Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed)" Expiration Date *Modified to read November 20, 2024*

NOT-AG-23-061 Notice of Intent to Publish a Notice of Funding Opportunity for Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials (U24 Clinical Trial Not Allowed). The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. First Estimated Application Due Date: June 07, 2024.

Parent Announcements

NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates *Expiration Date: May 8, 2023.* **Modified *Expiration Date: May 8, 2024***

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-20-185** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-20-184** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-20-183** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-20-200** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-20-195** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-20-194** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **PA-20-196** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

NOT-DA-25-027 Development and Application of Novel Chemical Approaches to Discover Therapeutic Targets for Substance Use Disorders. The purpose of this NOSI is to encourage research on the development and application of novel chemical approaches and tools to gain a better understanding of the biological processes, targets, and pathways that could be exploited for the development of therapeutics for the treatment of substance use disorders (SUDs). This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through May 8, 2027.

NOT-HL-23-110 Data Informed, Place-Based Community-Engaged Research to Advance Health Equity. The purpose of this NOSI is to stimulate community-engaged research that leverages geospatial data to probe the influence of geographic factors on disease development and health outcomes. Our goal is to use place-based research to help advance health equity in different communities. Applicants must select the IC and associated NOFO to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that NOFO. This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 7, 2027. This NOSI expires on January 8, 2027.

Notice of Funding Opportunity (NOFO)

1. RFA-CA-24-008 Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed). This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program**.**

Due dates: April 01, 2024; October 01, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 17 awards, corresponding to a total of $4,200,000, for fiscal year 2025 . Future year amounts will depend on annual appropriations. Application budgets are limited to $150,000 per year (direct costs). The total project period request may not exceed 3 years.

2. RFA-CA-24-009 Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed). This Notice of Funding Opportunity Announcement (NOFO) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This

NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Due dates: April 01, 2024; October 01, 2024 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 10 awards, corresponding to a total of $4,300,000, for the fiscal year 2025. Future year amounts will depend on annual appropriations. Application budgets are limited to $300,000 per year (in direct costs). The total project period request may not exceed 3 years.

3. RFA-CA-24-010 Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed). This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Due dates: April 01, 2024; October 01, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 4 awards, corresponding to a total of $1,000,000, for the fiscal year 2025 . Future year amounts will depend on annual appropriations. Application budgets are limited to $150,000 per year (in direct costs). The total project period request may not exceed 3 years.

4. RFA-CA-24-011 Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed). This NOFO solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities

being developed, are not appropriate for this NOFO and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Due dates: April 01, 2024; October 01, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 2 awards, corresponding to a total of $900,000, for fiscal year 2025 . Future year amounts will depend on annual appropriations. Application budgets are limited to $300,000 per year (in direct costs). The total project period request may not exceed 3 years.

5. RFA-CA-24-013 Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional). The purpose of this NOFO is to encourage revision applications from *currently funded NCI U01 research projects*. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. This NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Due dates: April 01, 2024; October 01, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 3 awards, corresponding to a total of $600,000, for the fiscal year 2025 . Future year amounts will depend on annual appropriations. Application budgets may not exceed $150,000 in direct costs per year. Applicants may request support for up to 2 years, not to exceed the remaining number of years on the parent award.

6. RFA-DA-24-042 BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Optional). This NOFO seeks applications proposing a set of planning activities that will lay the groundwork for a scientific project aimed at integrating complementary theories and methods to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the level of the organism, with synchronous capture of changes in the organism's social or physical environment; and 2) develop data science and computational methods that allow for integration of multidimensional behavioral and environmental data representing multiple timescales, and that will establish of a conceptual and/or computational model of behavior as a complex dynamic system. Prospective projects are expected to be designed with the potential to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. The purpose of this R34 planning grant opportunity is to support planning and development of the research framework, design, and approach, including activities that will establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for a U01, or equivalent, NIH research award. his NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Due dates: February 15, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Budget: The NIH BRAIN Initiative intends to commit an estimated total of $2.2M to fund an estimated six awards. Application budgets should reflect the actual needs of the proposed project. The combined budget for direct costs for the two-year project period may not exceed $450,000. No more than $225,000 may be requested in any single year. he scope of the proposed project should determine the project period. The maximum project period is two years.

7. RFA-DK-23-021 Cardiovascular Repository – Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed). Cardiovascular complications are the leading cause of death for individuals with type 1 diabetes (T1D) and

significantly shorten their lives. Cardiovascular disease (CVD) progression in people with T1D differs from that observed in people with type 2 diabetes (T2D) and residual increased risk of CVD remains after treatment of standard risk factors, such as hyperglycemia, hypertension, and hyperlipidemia. The NIH Cardiovascular Repository for T1D (CaRe-T1D) was initiated with the goal of establishing a biorepository of human CV tissue and a scientific consortium to advance and support discovery and mechanistic research that increase the understanding of CVD in T1D. The first phase launched the biorepository and now in the second phase investigative teams will be added to form a consortium with the biorepository serving as the Coordinating Center (CC). CaRe-T1D is currently collecting hearts, kidneys, carotid and peripheral arteries, and blood from organ donors with T1D, T2D and without diabetes. The goal of this NOFO is to attract investigative teams with complementary interests and expertise who will leverage these resources through individual and collaborative studies to advance our knowledge of the pathogenesis of CVD in T1D.

Due dates: April 11, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDDK intends to commit $7.3 million to fund six to eight awards in FY2024. Application budgets cannot exceed $600,000 in direct costs in any year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

8. RFA-FD-24-007 Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed. Complex generic drug products represent an increasing share of the generic marketplace and may have distinct user interface differences compared to reference listed drug (RLD) products. A modernized post-market surveillance approach is needed to compare clinical outcomes between complex generic products and their corresponding RLD products to monitor for potential issues with therapeutic equivalence and to inform regulatory decision making. Real-world data (RWD) combined with machine learning (ML) and/or artificial intelligence (AI) could help to identify post-market signals efficiently in an automated and repeatable fashion, facilitating timely regulatory action. The purpose of this funding opportunity is to develop and test an AI- or ML-based algorithmic RWD model for post-market surveillance of complex generic drug products.

Due dates: March 31, 2024 by 11:59 PM Eastern United States Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for two (2) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/CDER intends to commit up to $300,000 in FY 2024 to fund one (1) award. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect) of $300,000 per year. The scope of the proposed project should determine the project period. The maximum project period is three (3) years.

Faculty of Medicine and Health Sciences **Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)** 009 Kth Floor, Teaching Block, Tygerberg Campus.	**Stellenbosch Campus** **Division for Research Development (DRD)** 2041 Krotoa Building, Ryneveld Street
Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za	**Enquiries:** research@sun.ac.za
Add "*Interest in NIH opportunity*" in the subject line. Add the *notice number* in the text of the email.	